<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="hwp">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="pmc">neurology</journal-id><journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28446646</article-id><article-id pub-id-type="pmc">5440239</article-id><article-id pub-id-type="publisher-id">NEUROLOGY2016780080</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000003960</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>20</subject><subject>321</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Randomized controlled trial of deutetrabenazine for tardive dyskinesia</article-title><subtitle>The ARM-TD study</subtitle></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Fernandez</surname><given-names>Hubert H.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Dr. Fernandez is in the Steering Committee/Advisory Board of Solvay Duodopa Global Study and EMD Serono Safinamide Global Study, and the Coordinating Investigator for the Xeomin Registry, but has not received any personal compensation for these activities.</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Dr. Fernandez has received honoraria from USF CME, Cleveland Clinic CME, Medical Communications Media, Health Professions Conferencing, Ipsen, Merz Pharmaceuticals, US World Meds, Prime Education Inc., Ohio State University, International Parkinson and Movement Disorders Society, Carline Communications, Medscape (as a speaker in CME events), Biogen GE Healthcare, Lundbeck, Merz, Pfizer (as a consultant).</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Dr. Fernandez has received a stipend from Movement Disorders Society for serving as Medical Editor of the MDS Web Site.</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>Dr. Fernandez is a patent co-owner of COMPRESS, a neurosurgical candidate selection tool.</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>Dr. Fernandez has received royalty payments from Demos Publishing, Manson Publishing, Springer Publishing for serving as a book author.</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Dr. Fernandez has received research support from: AbbVie, Acadia, Auspex/Teva, Biotie Therapeutics, Civitas, Kyowa/Prostrakan, Michael J. Fox Foundation, Movement Disorders Society, Parkinson Study Group, Rhythm, Synosia, Abbott, but has no owner interest in any pharmaceutical company. Contractual Services: AbbVie, Merz Pharmaceuticals, Auspex/Teva, Xeomin Registry Study, Ipsen Pharmaceuticals.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>Dr. Fernandez has received research support from NIH/NINDS</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>Dr. Fernandez has received research support from Huntington Study Group, Movement Disorders Society, Parkinson Study Group</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Dr. Fernandez has received research support from Michael J. Fox Foundation, Movement Disorders Society, National Parkinson Foundation,, Society of Progressive Supranuclear Palsy.</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>Dr. Fernandez received Royalties: Demos Publishing.</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Factor</surname><given-names>Stewart A.</given-names></name><degrees>DO</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Lundbeck - Data safety monitoring board UCB - consultant Avanir - Consultant and video reviewer for a clinical trial Neurocrine - consultant and video reviewer for a clinical trial Auspex/Teva - consultant and video reviewer for a clinical trial Cynapsus: advisory board US World Meds consultant Adamas Consultant</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Neurotherapeutics 2014</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>(1)Parkinson's Disease Diagnosis and Clinical management, Demos, 2008 (2) Drug Induced Movement Disorders, Blackwell Futura, 2005 930 Uptodate</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other activities:</title><list-item><p>Research grants From Cynapsus/Sunovion, TEVA, Ipsen, US World Meds Medtronics, Auspex, Teva, Pharm-Olam, Solstice, Vaccinex Michael J. Fox Foundation, NIH</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Research grants From Ceregene, Cynapsus, TEVA, Ipsen, US World Meds Allergan, Medtronics, Auspex, Solstice, Pharm-Olam, Michael J. Fox Foundation, NIH</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>1 U10 NS077366-01 (PI Stewart Factor, DO) 9/30/2011-8/31/16 NINDS Emory Clinical research site for NEXT Phase II infrastructure for neurological clinical trials.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>PPMI (Site PI: Factor) 7/15/2010-7/14/2015 The Michael J. Fox Foundation The Parkinson?s Progression Markers Initiative (PPMI) National Parkinson Foundation Huntington's Society of America An observational trial examining clinical, biological (serum, urine, CSF) and imaging markers for early Parkinson?s disease to enhance the ability to measure progression of disease.</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>KMart - Expert witness, 2014-16</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Hauser</surname><given-names>Robert A.</given-names></name><degrees>MD, MBA</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Guidepoint Global, Gerson Lehrman Group (GLG), LCN Consulting, Putnam Associates, National Parkinson Foundation (NPF), eResearch Technology, Inc., Lundbeck LLC, Cynapsus Therapeutics, Sarepta Therapeutics, Adamas Pharmaceuticals, Neurocrine Biosciences, Back Bay Life Science, US WorldMeds, Biotie Therapies, Michael J. Fox Foundation (MJFF), Neuropore Therapies, National Institutes of Health (NIH), Projects in Knowledge, Prexton Therapeutics, Acorda Therapeutics, Vista Research, LifeMax, Peerview Press, ClinicalMind Medical and Therapeutic Communications, Sunovion Pharmaceuticals, Inc., Academy for Continued Healthcare Learning, Outcomes Insights, Expert Connect, HealthLogix, Teva Pharmaceutical Industries, Cowen and Company, Pharma Two B, Ltd, Pfizer, Inc., RMEI Medical Education for Better Outcomes, ClearView Healthcare Partners, Health Advances, Kyowa Kirin Pharmaceutical Development, Ltd., Impax Laboratories, Quintiles, Pfizer Inc., AbbVie Inc., AstraZeneca, Eli Lilly &#x00026; Company.</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Guidepoint Global, Gerson Lehrman Group (GLG), LCN Consulting, Putnam Associates, National Parkinson Foundation (NPF), eResearch Technology, Inc., Lundbeck LLC, Cynapsus Therapeutics, Sarepta Therapeutics, Adamas Pharmaceuticals, Neurocrine Biosciences, Back Bay Life Science, US WorldMeds, Biotie Therapies, Michael J. Fox Foundation (MJFF), Neuropore Therapies, National Institutes of Health (NIH), Projects in Knowledge, Prexton Therapeutics, Acorda Therapeutics, Vista Research, LifeMax, Peerview Press, ClinicalMind Medical and Therapeutic Communications, Sunovion Pharmaceuticals, Inc., Academy for Continued Healthcare Learning, Outcomes Insights, Expert Connect, HealthLogix, Teva Pharmaceutical Industries, Cowen and Company, Pharma Two B, Ltd, Pfizer, Inc., RMEI Medical Education for Better Outcomes, ClearView Healthcare Partners, Health Advances, Kyowa Kirin Pharmaceutical Development, Ltd., Impax Laboratories, Quintiles, Pfizer Inc., AbbVie Inc., AstraZeneca, Eli Lilly &#x00026; Company.</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Guidepoint Global, Gerson Lehrman Group (GLG), LCN Consulting, Putnam Associates, National Parkinson Foundation (NPF), eResearch Technology, Inc., Lundbeck LLC, Cynapsus Therapeutics, Sarepta Therapeutics, Adamas Pharmaceuticals, Neurocrine Biosciences, Back Bay Life Science, US WorldMeds, Biotie Therapies, Michael J. Fox Foundation (MJFF), Neuropore Therapies, National Institutes of Health (NIH), Projects in Knowledge, Prexton Therapeutics, Acorda Therapeutics, Vista Research, LifeMax, Peerview Press, ClinicalMind Medical and Therapeutic Communications, Sunovion Pharmaceuticals, Inc., Academy for Continued Healthcare Learning, Outcomes Insights, Expert Connect, HealthLogix, Teva Pharmaceutical Industries, Cowen and Company, Pharma Two B, Ltd, Pfizer, Inc., RMEI Medical Education for Better Outcomes, ClearView Healthcare Partners, Health Advances, Kyowa Kirin Pharmaceutical Development, Ltd., Impax Laboratories, Quintiles, Pfizer Inc., AbbVie Inc., AstraZeneca, Eli Lilly &#x00026; Company.</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1) Guidepoint Global, (2) Gerson Lehrman Group, (3) LCN Consulting, (4) Putnam Associates, (5) National Parkinson Foundation, (6) eResearch Technology, Inc., (7) Lundbeck LLC, (8) Cynapsus Therapeutics, (9) Sarepta Therapeutics, (10) Adamas Pharmaceuticals, (11) Neurocrine Biosciences, (12) Back Bay Life Science, (13) Teva Pharmaceuticals, (14) US WorldMeds, (15) Biotie Therapies, (16) Michael J. Fox Foundation, (17) Neuropore Therapies, (18) National Institutes of Health, (19) Projects in Knowledge, (20) Prexton Therapeutics, (21) Acorda Therapeutics, (22) Vista Research, (23) LifeMax, (24) Peerview Press, (25) ClinicalMind Medical and Therapeutic Communications, (26) Sunovion Pharmaceuticals, Inc., (27) Academy for Continued Healthcare Learning, (28) Outcomes Insights, (29) Expert Connect, (30) HealthLogix, (31) Cowen and Company, (32) Pharma Two B, Ltd, (33) Pfizer, Inc., (34) RMEI Medical Education for Better Outcomes, (35) AbbVie, (36) Astrazeneca, (37) Axovant, (38) Biotie, (39) Civitas/Acorda, (40) Enterin, (41) Impax, (42) Intec, (43) Jazz Pharma, (44) Kyowa Kirin Pharmaceutical Development, Inc, (45) Neuroderm, (46) The Parkinson's Progression Markers Initiative</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>(1) The Michael J. Fox Foundation for Parkinson?s Research; (2) The Parkinson Foundation</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>University of South Florida</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Jimenez-Shahed</surname><given-names>Joohi</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>St. Jude Medical, funding for travel Medtronic, funding for travel Biotie, funding for travel</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Teva St. Jude Medical Medtronic</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Acadia Pharmaceuticals St. Jude Medical Biotie Therapeutics Solstice Neurosciences Avid Radiopharmaceuticals</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>Massachusetts General Hospital</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Michael J Fox Foundation</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Ondo</surname><given-names>William G.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>has served as a consultant or an advisor for Acadia, Acorda, Avanir, Impax, Lundbeck, Merz, Teva, and UCB Pharma</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>has served as a consultant or an advisor for Abbvie, Acadia, Auspex, Avanir, Impax, Lundbeck, Merz, Teva, and UCB Pharma</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>TEVA UCBPharma Lundbeck ACADIA Xenoport Avanir</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Cynapsus</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Huntington Study Group Tremor Research Group</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Jarskog</surname><given-names>L. Fredrik</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>(1) Clintara</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1) Auspex/Teva, (2) Boehringer Ingelheim, (3) Otsuka</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>1) NIH, DK105526, PI, 2016-present, (2) NIH, MH105574, PI, 2014-present, (3) NIH, DA032533, site-PI, 2014-2016, (4) NIH, MH090833, site-PI, 2012-2015, (5) NIH, MH081107, Co-investigator, 2011-2015</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Meltzer</surname><given-names>Herbert Y.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Advisory board for TEVA and NEUROCRINE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Woods</surname><given-names>Scott W.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Boehringer-Ingelheim</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1) Teva</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>(1) National Institute of Mental Health, U01 MH082022 , 2008-2019 (2) National Institute of Mental Health, U01 MH082022-06S1, 2015-2019</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Bega</surname><given-names>Danny</given-names></name><degrees>MD, MSCI</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>(1) Acadia Pharmaceuticals, speaker honoraria (2) Huntington Study Group, travel reimbursement (3) Parkinson Study Group, travel reimbursement</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>(1) Teva Pharmaceuticals (2) Cynapsus Therapeutics</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>Acadia Pharmaceuticals</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>LeDoux</surname><given-names>Mark S.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(1) Chairman, Board of Medical Advisors, National Spasmodic Torticollis Association (2) Member, Scientific Advisory Board, Spastic Paraplegia Foundation</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>(1)Lundbeck, Speaker, 2010 - present (2)Acadia, Speaker, 2016 - present</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Parkinsonism and Related Disorders, Editorial Board, 2008-2016. Tremor and Other Hyperkinetic Movement Disorders, Editorial Board, 2011-present. PLOS ONE, 2014-present. Neurology, 2015-present.</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>Elsevier, Animal Models of Movement Disorders, 2005- present. Elsevier, Movement Disorders: Genetics and Models, 2015- present</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>(1) University of Tennessee Health Science Center, 1997- present (2) Wesley Neurology Clinic, 2013 - present</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>1) Consultant, Mayo Clinic, 2013 - present.</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>(1)Lundbeck, Speaker, 2010 - present (2)Acadia, Speaker, 2016 - present</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1) CHDI,Enroll-HD, July 2012 to present (2) Prana Biotechnology, Reach2HD, July 2012 to April 2013 (3) Omeros, Phase 2 Randomized, Double-Blind, Placebo- Controlled, Sequential Cohort Study to Evaluate Safety and Efficacy of OMS643762 in Subjects with Huntington?s Disease, June 2014-present (4)Auspex/Teva, SD-809-C-18 and SD-809-C-20, Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia and SD809-C-20 An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia (LeDoux-Site PI), 9/22/2014 - present (5) US WorldMeds, Mysticol, Protocol SN-SIAL-301, ?A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety study of MYOBLOC? (Part A) Followed by Open-Label, Multiple-Treatment with MYOBLOC? (Part B) in the Treatment of Troublesome Sialorrhea in Adult Subjects (LeDoux - Site PI), 11/1/2014 - present (6)Auspex/Teva, SD-809-C-23, Randomized, Double-Blind, Placebo- Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia (LeDoux-Site PI), 03/03/2015 - present (7) Accorda, DALF-PS-1016, (MILESTONE) A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke(LeDoux- Site PI), 01AUG2015 - present (8) US WorldMeds, OPTIMYST, Protocol SN-SIAL-351, ?Open- Label and Single- Arm Study of MYOBLOC? in the Treatment of Troublesome Sialorrhea in Adults (LeDoux- Site PI), 15DEC2015 - present</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>(1) National Institutes of Health, 1U54 TR001456, Prospective Natural History Study and Biorepository, May 2011 to present (2) NIH/NINDS, R01NS069936, The Role of THAP1 in Dystonia, August 2010 to 2014 (3)NIH/NCCAM 5U01AT000613, ?CREST-E,? (Steven M. Hersch, PI; Mark LeDoux, Site-PI) Creatine Safety, Tolerability, and Efficacy in Huntington?s Disease, 01OCT2010-30SEP2015 (4)NIH/NINDS, ?2CARE?, (Merit Cudkowicz-PI; LeDoux-Site PI) 2CARE is a definitive long-term, multi-center, placebo-controlled clinical trial of high dose coenzyme Q10 (CoQ) in Huntington?s disease. 01APR2008-30JUN2014 (5)NIH/NINDS, R01NS082296, Genetics and Biology of CIZ1 in Cervical Dystonia, 13SEP2013-30JUN2017 (6) R21 GM118962, The Role of UBTF in Undiagnosed Neurodevelopmental Disorders, NIH(Hori and LeDoux, Co- PIs) 05/06/2016 - 04/30/2018 (7)5U01NS090259 (LeDoux - Site PI), NIH/NINDS, ?Study of Urate Elevation in Parkinson's Disease, Phase 3 (SURE- PD3)? 09/09/16- present</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Benign Essential Blepharospasm Research FDN, ?Genetics of Blepharospasm? LeDoux-PI), 01/01/15 - 12/31/16</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>1) Starnes-Davis-Florie, expert consultant, 2016 2) Spears, Moore, Rebman &#x00026; Williams, expert consultant, 2016 3) Elite Medical, expert consultant, 2016</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Shprecher</surname><given-names>David R.</given-names></name><degrees>DO, MS</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>1. Tourette Syndrome Association of America 2. Teva 3. Lundbeck</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>1. Teva 2. Lundbeck</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>1. Teva 2. Neurocrine 3. Kyowa 4. ADAMAS 5. Intec 6. Biotie 7. Axovant</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>1. Arizona Alzheimer's Consortium 2. Michael J Fox Foundation</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Davis</surname><given-names>Charles</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Dr. Davis has consulted for the following companies: (1) Acadia Pharmaceuticals, (2) Accera Pharmaceuticals, (3) Acino Pharmaceuticals, (4) Adamas Pharmaceuticals, (5) Adamis Pharmaceuticals (6) Aerogen Pharma,(7) Agility Pharma, (8) Aimmune Therapeutics, (9) Alvine Pharmaceuticals, (10) Amplyx Pharmaceuticals, (11) Amryt Pharma, (12) Angionetics Inc, (13) Ansun Biopharma, (14) Anthera Pharmaceuticals, (15) Arena Pharmaceuticals, (16) Astellas Pharma, (17) Atara Biotherapeutics, (18) Attenua Inc, (19) Auspex Pharmaceuticals, (20) Avanir Pharmaceuticals, (21) BioCardia Inc, (22) BioNevia Pharmaceuticals, (23) Blood Hurst and O?Riordan LLP, (24) CURx Pharma, (25) Capnia Inc, (26) Taxus Cardium Pharmaceuticals, (27) Chiasma Pharma, (28) Clinica Santa Clarita, (29) Cognition Therapeutics, (30) Cognitive Research Corporation, (31) Conatus Pharmaceuticals, (32) Corcept Therapeutics, (33) Crescendo Bioscience, (34) CymaBay Therapeutics, (35) CytRx Corporation, (36) DSC Associates Inc, (37) Dako (an Agilent Technologies Company), (38) Dance BioPharma, (39) Eagle Pharmaceuticals, (40) Evofem Biosciences, (41) Finox AG Biotech, (42) Fairmount Healthcare Funds, (43) Galena Biopharma, (44) Genoa Pharmaceuticals, (45) Gradalis Inc, (46) Great Point Partners, (47) HealthQuest Capital, (48) Histogen Inc, (49) Hoffmann Eitle, (50) Humacyte Inc, (51) Imaging Services (radiology company in Los Angeles), (52) Intercept Pharmaceuticals, (53) JW Consulting LLC, (54) Jazz Pharmaceuticals, (55) Kurth (clinical consulting company), (56) Lenczner Slaght, (57) Lipocine Inc, (58) Lupin Pharmaceuticals, (59) MediciNova Inc, (60) Meritage Pharma, (61) Metacrine Inc, (62) Milestone Pharmaceuticals, (63) Mirna Therapeutics, (64) Morgan Lewis, (65) MyoKardia Inc, (66) Nektar Therapeutics, (67) Nestec Inc, (68) Neumedicines Inc, (69) NeuroPhage Pharmaceuticals, (70) NovaBay Pharmaceuticals, (71) NovaRx Corporation, (72) Ocera Therapeutics, (73) Omniox Inc, (74) OncoSec Medical Inc, (75) Opiant Pharmaceuticals, (76) OrthoTrophix Inc, (77) Pacific-Link Regulatory Consulting, (78) Patara Pharma, (79) Plexxikon Pharmaceuticals, (80) Poseida Therapeutics, (81) Precision Oncology, (82) Prothena Corporation, (83) Questcor Pharmaceuticals, (84) Receptos, (85) Red House Investments, (86) Regulus Therapeutics, (87) Resverlogix Corp, (88) Ritter Pharmaceuticals, (89) SAJE Consulting, (90) Salamandra LLC, (91) Sofinnova, (92) Solinas Medical, (93) Sommetrics Inc, (94) Sophiris Bio, (95) Structured Bioequity Inc, (96) Symbiomix Therapeutics, (97) Synlogic Therapeutics, (98) TauRx Therapeutics, (99) Tavistock Group, (100) Tioga Pharmaceuticals, (101) Tobira Therapeutics, (102) Virtual Regulatory Solutions, (103) Valensa, (104) Valor Pharmaceuticals, (105) Vivo Capital, (106) Zafgen Inc, (107) Zogenix Inc</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other activities:</title><list-item><p>Dr. Davis served on DMCs for the following companies: (1) AB2 Bio LTD, (2) AbbVie, (3) Alder Biopharmaceuticals, (4) Alfa Wassermann Inc, (5) Allergan, (6) Amgen, (7) Ardea Biosciences, (8) AstraZeneca, (9) Balance Therapeutics, (10) Banner Pharmacaps, (11) Baxalta, (12) Biogen, (13) Caladrius Biosciences, (14) Cempra Pharmaceuticals, (15) Cytokinetics Inc, (16) Eiger Biopharmaceuticals, (17) Fate Therapeutics, (18) FibroGen Inc, (19) Gilead, (20) Gore, (21) Halozyme Therapeutics, (22) Indivior PLC, (23) Ionis Pharmaceuticals, (24) MedImmune, (25) Menlo Therapeutics, (26) Nora Therapeutics, (27) NovaBiotics LTD, (28) Novartis, (29) Nutrinia, (30) Ocata Therapeutics, (31) Omeros, (32) Otsuka, (33) Pfizer, (34) Protagonist Therapeutics, (35) Purdue Pharma, (36) SIGA Technologies, (37) SanBio Inc, (38) Sunovion, (39) Takeda, (40) Threshold Pharmaceuticals, (41) Tracon Pharmaceuticals, (42) TriReme Medical, (43) Ultragenyx Pharmaceutical Inc, (44) VBL Therapeutics, (45) Vical Inc, (46) Zoll Circulation</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Davis</surname><given-names>Mat D.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Teva Pharmaceuticals, 3 years</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>Teva Pharmaceuticals, 2.5 years</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Stamler</surname><given-names>David</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Dr. Stamler is an employee of Teva Pharmaceutical Industries; and received personal fees from Auspex Pharmaceuticals, outside the submitted work.</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>Karen E.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>1- 2CARE DSMB Member 2- PRE CELL DSMB Member 3- Teva Scientific Advisory Board Member</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>1- Teva- Educational courses taught 2- Auspex- Advisory Board attendance 4-CHDI travel funding</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>1- percent of salary effort covered by Teva for work as Co PI for LEGATO HD study 2- percent of salary funded by Teva for work on Tardive Dyskinesia ARM and AIM studies 3- Percent of salary covered by Azevan/NINDS for consultant on STAIR HD NeuroNext study.</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>1- Teva- advisory board attendance, donated to Huntington Study Group 2- Auspex- Advisory Board attendance 3- Teva Advisory Board for Tardive Dyskinesia 3- Prana - consultant</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>Griffin Foundation Salary funding through Georgetown University.</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>1- Teva 2- auspex 3- Azevan 4- Griffin Foundation</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NINDS</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>1- Georgetown University- salary and research support</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Griffin Foundation</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><aff>From the Cleveland Clinic (H.H.F.), Center for Neurological Restoration, Cleveland, OH; Emory University (S.A.F.), Atlanta, GA; University of South Florida Parkinson's Disease and Movement Disorders Center (R.A.H.), Tampa, FL; Baylor College of Medicine (J.J.-S.), Houston, TX; Methodist Neurological Institute (W.G.O.), Houston, TX; University of North Carolina School of Medicine (L.F.J.), Chapel Hill, NC; Northwestern University Feinberg School of Medicine (H.Y.M., D.B.), Chicago, IL; Yale School of Medicine (S.W.W.), New Haven, CT; University of Tennessee Health Science Center (M.S.L.), Memphis, TN; University of Utah Health Care (D.R.S.), Salt Lake City, UT; Banner Sun Health Research Institute (D.R.S.), Sun City, AZ; CSD Biostatistics (C.D.), Tucson, AZ; Teva Pharmaceutical Industries (M.D.D.), Frazer, PA; Teva Pharmaceuticals (D.S.), La Jolla, CA; and Georgetown University (K.E.A.), Washington, DC.</aff></contrib-group><author-notes><corresp>Correspondence to Dr. Fernandez: <email>fernanh@ccf.org</email></corresp><fn fn-type="financial-disclosure"><p>Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000003960">Neurology.org</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was funded by Teva Pharmaceutical Industries.</p></fn></author-notes><pub-date pub-type="ppub"><day>23</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>. --><volume>88</volume><issue>21</issue><fpage>2003</fpage><lpage>2010</lpage><history><date date-type="received"><day>03</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>03</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="NEUROLOGY2016780080.pdf"/><abstract><sec><title>Objective:</title><p>To determine the efficacy and safety of deutetrabenazine as a treatment for tardive dyskinesia (TD).</p></sec><sec><title>Methods:</title><p>One hundred seventeen patients with moderate to severe TD received deutetrabenazine or placebo in this randomized, double-blind, multicenter trial. Eligibility criteria included an Abnormal Involuntary Movement Scale (AIMS) score of &#x02265;6 assessed by blinded central video rating, stable psychiatric illness, and stable psychoactive medication treatment. Primary endpoint was the change in AIMS score from baseline to week 12. Secondary endpoints included treatment success at week 12 on the Clinical Global Impression of Change (CGIC) and Patient Global Impression of Change.</p></sec><sec><title>Results:</title><p>For the primary endpoint, deutetrabenazine significantly reduced AIMS scores from baseline to week 12 vs placebo (least-squares mean [standard error] &#x02212;3.0 [0.45] vs &#x02212;1.6 [0.46], <italic>p</italic> = 0.019). Treatment success on CGIC (48.2% vs 40.4%) favored deutetrabenazine but was not significant. Deutetrabenazine and placebo groups showed low rates of psychiatric adverse events: anxiety (3.4% vs 6.8%), depressed mood/depression (1.7% vs 1.7%), and suicidal ideation (0% vs 1.7%, respectively). In addition, no worsening in parkinsonism, as measured by the Unified Parkinson's Disease Rating Scale motor subscale, was noted from baseline to week 12 in either group.</p></sec><sec><title>Conclusions:</title><p>In patients with TD, deutetrabenazine was well tolerated and significantly reduced abnormal movements.</p></sec><sec><title>Classification of evidence:</title><p>This study provides Class I evidence that in patients with TD, deutetrabenazine reduces AIMS scores.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>special-property</meta-name><meta-value>podcast</meta-value></custom-meta><custom-meta><meta-name>special-property</meta-name><meta-value>triangle</meta-value></custom-meta><custom-meta><meta-name>cme</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Tardive dyskinesia (TD) is a movement disorder resulting from exposure to dopamine receptor antagonists (DRAs), including typical and atypical antipsychotics, antiemetics, and metoclopramide.<sup><xref rid="R1" ref-type="bibr">1</xref><xref ref-type="bibr" rid="R2">&#x02013;</xref><xref rid="R3" ref-type="bibr">3</xref></sup> TD can affect any part of the body and be debilitating.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup> Approximately 20% to 50% of patients receiving antipsychotics develop TD.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> The pathophysiology of TD is unknown, but upregulation and sensitization of D2 receptors after prolonged blockade may be contributory.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup> Continued DRA use may worsen symptoms,<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup> while dose reduction can increase the risk of psychiatric relapse or acutely worsen TD.<sup><xref rid="R7" ref-type="bibr">7</xref><xref ref-type="bibr" rid="R8">&#x02013;</xref><xref rid="R10" ref-type="bibr">10</xref></sup> In &#x0003e;80% of patients, TD appears irreversible, even after the causative agent is discontinued.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> There are currently no US Food and Drug Administration&#x02013;approved treatments for TD.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> Although some off-label treatments have been studied for the management of TD,<sup><xref rid="R8" ref-type="bibr">8</xref></sup> a significant unmet need remains for a tolerable and efficacious treatment option that allows the continuation of concomitant DRA use for underlying comorbidities.</p><p>Tetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor that modulates synaptic dopamine.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> Tetrabenazine is rapidly and extensively converted in the liver to alpha and beta active metabolites, which are potent and selective inhibitors of VMAT2.</p><p>These active metabolites have short half-lives that necessitate frequent dosing and result in large plasma fluctuations that are thought to contribute to the poor tolerability often observed.<sup><xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref></sup> Conventional tetrabenazine-associated neuropsychiatric adverse events (AEs), including somnolence, depression, insomnia, akathisia, and parkinsonism, may limit its use.<sup><xref rid="R13" ref-type="bibr">13</xref></sup></p><p>Deutetrabenazine is a novel, highly selective VMAT2 inhibitor containing deuterium, a naturally occurring, nontoxic form of hydrogen.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> Incorporation of deuterium attenuates metabolism, leading to decreased plasma fluctuations compared with conventional tetrabenazine,<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> with potential to reduce AEs associated with peak concentrations. For example, deutetrabenazine significantly decreased chorea, improved overall motor function, and was well tolerated, with low rates of neuropsychiatric symptoms in patients with Huntington disease (HD),<sup><xref rid="R19" ref-type="bibr">19</xref></sup> a population with high psychiatric comorbidity.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> This study evaluates the efficacy, safety, and tolerability of deutetrabenazine for the treatment of TD.</p><sec sec-type="methods" id="s1"><title>METHODS</title><sec id="s1-1"><title>Primary research question.</title><p>Is deutetrabenazine effective at reducing the severity of abnormal involuntary movements of TD as measured using the Abnormal Involuntary Movement Scale (AIMS) score? This study provides Class I evidence that in patients with TD, deutetrabenazine reduces AIMS scores.</p></sec><sec id="s1-2"><title>Standard protocol approvals, registrations, and patient consents.</title><p>This phase II/III trial is registered at <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (NCT02195700). Written approval of the study protocol was obtained from the independent ethics committee at each site. Informed consent was secured for each patient. This study was conducted from June 2014 to May 2015.</p></sec><sec id="s1-3"><title>Patient population.</title><p>Participants had a TD diagnosis for &#x02265;3 months before screening and a history of DRA treatment for &#x02265;3 months (&#x02265;1 month if age &#x02265;60 years). Patients were required to have investigator-assessed total AIMS motor score &#x02265;6 (examination of items 1&#x02013;7) at both screening and baseline, verified by a blinded central rater at screening. For logistic reasons, the video of the AIMS motor score at baseline could not be assessed by blinded central rating until after randomization. Psychoactive medication use, including antipsychotics, was allowed if stable for &#x02265;30 days before screening (antidepressants &#x02265;45 days).</p><p>Treatment with tetrabenazine, reserpine, &#x003b1;-methyl-p-tyrosine, strong anticholinergic medications, metoclopramide, dopamine agonists, levodopa, and/or stimulants within 30 days of screening or baseline was exclusionary, as was treatment with botulinum toxin within 3 months of screening. Other exclusions included presence of a neurologic condition that could confound TD assessments, serious untreated or undertreated psychiatric illness, or unstable medical illness. Patients with history of or active suicidal ideation or behavior within 6 months of screening or score &#x02265;11 on the depression subscale of the Hospital Anxiety and Depression Scale (HADS) were excluded. A corrected QT interval with the Fridericia formula (QTcF) of &#x0003e;450 milliseconds in men or &#x0003e;460 milliseconds in women on 12-lead ECG at screening was also exclusionary.</p></sec><sec id="s1-4"><title>Study design.</title><p>This was a 12-week, randomized, double-blind, parallel-group study conducted at 46 sites in the United States and Europe. Patients were centrally randomized 1:1 to receive deutetrabenazine or matching placebo and stratified by use of DRA at baseline (currently taking vs not currently taking a DRA). Randomization and stratification were performed through an Interactive Technology Response System. Both patients and site investigators remained blinded to treatment assignment throughout the study.</p><p>After randomization, study drug was started at 12 mg/d (6 mg twice daily) and titrated weekly by 6 mg/d, if required, for up to 6 weeks until adequate dyskinesia control was achieved, a significant AE occurred, or the maximal allowable dose (48 mg/d) was reached; this was followed by maintenance (6 weeks) and a 1-week washout. The investigator, in consultation with the patient and caregiver (if applicable), determined the optimal dose for dyskinesia control. In patients receiving a strong <italic>CYP2D6</italic> inhibitor, the maximum allowed dose of deutetrabenazine was 36 mg/d. Clinic visits and AIMS evaluations were performed at weeks 2, 4, 6, 9, 12, and 13. Telephone consultations occurred at weeks 1, 3, 5, and 7.</p></sec><sec id="s1-5"><title>Efficacy assessments.</title><p>The primary endpoint was change in AIMS score from baseline to week 12 as assessed by 2 blinded central video raters who were movement disorders experts. For each of the 7 body regions, a consensus AIMS rating was reached. Video recordings were blinded with respect to treatment, visit number, investigation site, and recording date. All videos for a single patient were reviewed by both raters in a single session.</p><p>Secondary endpoints included proportion of patients who experienced treatment success at week 12 on the Clinical Global Impression of Change (CGIC) and Patient Global Impression of Change (PGIC), 7-point Likert scales ranging from very much worse to very much improved. CGIC assessment occurred at weeks 2, 4, 6, 9, and 12. PGIC assessment occurred weeks 4, 6, 9, and 12. Treatment success on the CGIC and PGIC was defined as much improved or very much improved at week 12. The change from baseline in modified Craniocervical Dystonia Questionnaire (mCDQ-24) score was also measured. The mCDQ-24 contains domains that are relevant to TD, such as stigma, emotional well-being, pain, activities of daily living, and social/family life, thereby enabling the evaluation of the effect and significance of TD on patients' quality of life.</p><p>Because the baseline visit video could not be assessed by central raters before randomization, some of the enrolled patients had an AIMS motor score &#x0003c;6 when assessed by the central raters; these patients were enrolled in the study on the basis of an AIMS score of &#x02265;6 at baseline, as assessed by the local site rater. Therefore, a post hoc analysis of patients with centrally read AIMS motor scores &#x02265;6 at both screening and baseline was performed. Other efficacy endpoints such as CGIC, PGIC, and mCDQ-24 were also analyzed.</p></sec><sec id="s1-6"><title>Safety assessments.</title><p>AEs were monitored throughout the study and are reported after randomization. Dose reductions, suspensions, and withdrawals due to AEs were also monitored. ECG readings were measured at baseline and weeks 2 and 12; additional readings occurred at weeks 4, 6, and 9 for patients receiving medications that potentially prolong the QT interval. Assessment of Unified Parkinson's Disease Rating Scale motor subscale, Barnes Akathisia Rating Scale, HADS, Columbia Suicide Severity Rating Scale, and Epworth Sleepiness Scale scores occurred at baseline and all clinic visits. The Montreal Cognitive Assessment scale was performed at baseline and maintenance. Dosing decisions were made without knowledge of <italic>CYP2D6</italic> metabolism status.</p></sec><sec id="s1-7"><title>Statistical analysis.</title><p>Efficacy analyses were conducted in the modified intent-to-treat (mITT) population, which included all randomized patients who received study drug and had at least one postbaseline AIMS assessment. The safety population included patients who received at least one dose of study drug. The primary analysis of change in AIMS score from baseline was conducted with a linear mixed model for repeated measurements that included fixed effects for treatment group, time point, treatment group by time point interaction, and concomitant DRA use at baseline. Baseline AIMS score was included as a covariate, and the unstructured covariance model was used. The primary efficacy analysis compared treatment groups at week 12 with the use of a 2-sided test at the 5% significance level. Secondary endpoints, defined as proportions of patients with treatment success (e.g., CGIC and PGIC), were compared between treatment groups with the Pearson &#x003c7;<sup>2</sup> test. Change in mCDQ-24 score from baseline to week 12 was analyzed with an analysis of covariance model with treatment group and concomitant DRA use at baseline as factors, and with baseline mCDQ-24 score included as a covariate.</p></sec><sec id="s1-8"><title>Sample size.</title><p>A 2-sided test at 5% significance was applied and assumed an SD of 4.1 for the change from baseline to week 12 in AIMS score. Approximately 90 patients provided 90% power to detect a treatment difference of 2.8 units in the AIMS and 80% power to detect a treatment difference of 2.4 units.</p></sec></sec><sec sec-type="results" id="s2"><title>RESULTS</title><sec id="s2-1"><title>Patient baseline characteristics and disposition.</title><p>A total of 117 patients with TD were randomized to receive deutetrabenazine (n = 58) or placebo (n = 59). A comparable proportion of patients completed the study in both groups (<xref ref-type="fig" rid="F1">figure 1</xref>). Both groups had similar demographics and baseline characteristics (<xref ref-type="table" rid="T1">table 1</xref>). Approximately 70% of the population had an underlying diagnosis of schizophrenia or schizoaffective disorder (<xref ref-type="table" rid="T1">table 1</xref>); 23.1% had bipolar disorder; and 25.6% had depression. The majority of patients (80.3%) were being treated with a DRA at baseline and continued treatment throughout the study.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Flow of study patients</title><p>After screening for eligibility, 117 patients were randomized to receive deutetrabenazine or placebo. A total of 89.7% and 88.1% of patients completed 12 weeks of treatment with deutetrabenazine or placebo, respectively.</p></caption><graphic xlink:href="NEUROLOGY2016780080FF1"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patient baseline characteristics by treatment group</p></caption><graphic xlink:href="NEUROLOGY2016780080TT1"/></table-wrap></sec><sec id="s2-2"><title>Dose.</title><p>At the end of the titration period, the mean (SD) total daily dose was 38.8 (7.92) mg/d. The mean [SD] dose remained stable until the end of the treatment period (38.3 [7.97] mg/d).</p></sec><sec id="s2-3"><title>Efficacy assessments.</title><p>For the primary endpoint, deutetrabenazine significantly reduced AIMS scores from baseline to week 12 compared with placebo (least-squares [LS] mean [standard error (SE)]: &#x02212;3.0 [0.45] vs &#x02212;1.6 [0.46], <italic>p</italic> = 0.019; treatment difference &#x02212;1.4 [0.60], 95% confidence interval [CI] &#x02212;2.6 to &#x02212;0.2) (<xref ref-type="fig" rid="F2">figure 2</xref>). Improvement in AIMS score was different between the deutetrabenazine and placebo groups by week 4 with a treatment effect of &#x02212;1.5 (95% CI &#x02212;2.6 to &#x02212;0.4, <italic>p</italic> = 0.007).</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Mean change in AIMS score</title><p>AIMS score was assessed over 12 weeks by central video rating in the mITT population based on the linear mixed model for repeated measurements. The mean change in AIMS score from baseline at weeks 2, 4, 6, 9, and 12 is depicted. Error bars represent standard error. AIMS = Abnormal Involuntary Movement Scale; mITT = modified intent to treat. *<italic>p</italic> = 0.007. **<italic>p</italic> = 0.019.</p></caption><graphic xlink:href="NEUROLOGY2016780080FF2"/></fig><p>While the percentage of patients who achieved treatment success on the CGIC (48.2% vs 40.4%) and PGIC (42.9% vs 29.8%) favored deutetrabenazine, these differences were not statistically significant. Similarly, deutetrabenazine-treated patients had a greater LS mean [SE] reduction from baseline to week 12 in the mCDQ-24 score than placebo (&#x02212;11.1 [2.14] vs &#x02212;8.3 [2.31]), but the difference was not statistically significant.</p><p>Of the 113 patients in the mITT population, 97 patients (85.8%) had a centrally read AIMS score &#x02265;6 at both screening and baseline<italic>.</italic> Because this subgroup represents the intended population for the study, a post hoc analysis was performed on the primary and key secondary endpoints. Similar to the overall population, for the AIMS, deutetrabenazine-treated patients had a greater decrease in LS mean [SE] scores compared with placebo (3.4 [0.48] vs 1.9 [0.51], <italic>p</italic> = 0.027; treatment difference &#x02212;1.5 [0.67], 95% CI &#x02212;2.8 to &#x02212;0.2) (<xref ref-type="fig" rid="F3">figure 3</xref>). In the same subpopulation, the difference in the percentage of patients who were classified as a treatment success on the basis of the CGIC widened between the deutetrabenazine vs placebo arms compared with the entire mITT cohort (25 [52.1%] vs 17 [34.7%], <italic>p</italic> = 0.084; treatment difference 17.4%, 95% CI &#x02212;2.2% to 35.3%). The treatment difference in this subpopulation was 17.4% compared with 7.9% in the mITT cohort. Compared with placebo, a greater percentage of deutetrabenazine-treated patients in this subpopulation had treatment success based on the PGIC (45.8% vs 28.6%). Patients in the deutetrabenazine group also had a greater LS mean [SE] reduction from baseline to week 12 in the mCDQ-24 total score (&#x02212;12.2 [2.21] vs &#x02212;6.6 [2.39]). Similar to the mITT population, these results were not statistically significant.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Analysis of treatment effect for efficacy parameters</title><p>(A) Treatment difference (deutetrabenazine&#x02013;placebo) of the LS mean change in AIMS score. (B) Proportion of patients who experience treatment success on the CGIC. Error bars for AIMS are standard error. AIMS = Abnormal Involuntary Movement Scale; CGIC = Clinical Global Impression of change; LS = least squares.</p></caption><graphic xlink:href="NEUROLOGY2016780080FF3"/></fig></sec><sec id="s2-4"><title>Safety assessments.</title><p>Patients from the deutetrabenazine and placebo groups reported similar rates of AEs. The most common AEs (&#x0003e;4% of patients in either group) are presented in <xref ref-type="table" rid="T2">table 2</xref>.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Patients who reported adverse events (AEs) in each treatment group</p></caption><graphic xlink:href="NEUROLOGY2016780080TT2"/></table-wrap><p>Treatment-related AEs were reported in 48.3% of the deutetrabenazine group compared with 35.6% of the placebo group. Notably, the incidence of several AEs of interest in the deutetrabenazine group, such as depression/depressed mood and suicidal ideation, was similar to or lower than for placebo.</p><p>Serious AEs were reported by 3 patients (5.2%) in the deutetrabenazine group and 5 patients (8.5%) receiving placebo. Serious AEs in the deutetrabenazine group included community-acquired pneumonia, substance-induced manic episode, and exacerbation of schizophrenia (n = 1 for each). Serious AEs in the placebo group included accidental heroin overdose, jaw fracture secondary to falling, jaw infection, pneumonia, and laryngeal hypertrophy (n = 1 for each). None were considered treatment related. There were no deaths during the study.</p><p>For the deutetrabenazine and placebo groups, there were relatively low rates of dose reductions, suspensions, and study withdrawals due to AEs, as presented in <xref ref-type="table" rid="T2">table 2</xref>.</p><p>Similar incidences of psychiatric AEs were observed in the overall deutetrabenazine group (20.7%) and in the cohort of patients taking deutetrabenazine with antipsychotics (19.6%), antidepressants (26.5%), or anxiolytics (23.1%). Deutetrabenazine treatment with concomitant antidepressants and anxiolytics was associated with similar rates of psychiatric AEs compared with placebo; however, there were more psychiatric AEs in patients treated with deutetrabenazine with antipsychotics compared with placebo (19.6% vs 9.8%). Nonetheless, the incidence of depressed mood, depression, and suicidal ideation remained low and was similar to that of the overall deutetrabenazine group in patients receiving concomitant antidepressants.</p><p>Small reductions in parkinsonism severity, as measured by the Unified Parkinson's Disease Rating Scale motor assessment, were observed from baseline to week 12 in the deutetrabenazine (mean [SD] change &#x02212;0.9 [8.09]) and placebo (&#x02212;3.8 [7.87]) arms. In addition, at week 12, there were no safety signals detected on the Barnes Akathisia Rating Scale, HADS-Anxiety, HADS-Depression, Epworth Sleepiness Scale, or Montreal Cognitive Assessment. No deutetrabenazine-treated patient reported suicidal ideation or behavior on the Columbia Suicide Severity Rating Scale, whereas 3 patients (5.2%) and 1 patient (1.7) in the placebo group reported suicidal ideation or behavior, respectively.</p><p>Finally, there were no meaningful differences in the QTcF interval prolongation between groups (<italic>p</italic> = 0.153). One placebo-treated patient exceeded a QTcF interval of 500 milliseconds.</p></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>This study demonstrated that deutetrabenazine is efficacious for the treatment of abnormal movements in patients with TD, with a favorable safety and tolerability profile that enables the continued use of DRAs and antidepressants for the management of chronic psychiatric conditions. Almost all patients (98.3%) enrolled in Aim to Reduce Movements in Tardive Dyskinesia (ARM-TD) had an underlying psychiatric comorbidity for which they were receiving concomitant medications, making these results especially relevant to clinical practice for clinicians managing similar patients in a real-world setting.</p><p>In general, deutetrabenazine was well tolerated, as supported by the high study completion rate and infrequent dose reductions, dose suspensions, or withdrawals. These results are of particular importance because antipsychotic discontinuation or dose reduction is often not possible for patients with TD because of the high risk of psychotic exacerbation.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> Moreover, deutetrabenazine did not result in reports of depression or suicidal ideation and was associated with low rates of psychiatric AEs, including anxiety.</p><p>Because of possible differences between on-site and centralized video ratings of TD, natural variation in the severity of dyskinesia, and potential differences among patients' subjective feelings (e.g., more nervous during the initial video) at screening vs baseline, 20 enrolled patients had AIMS scores &#x0003c;6 as assessed by a central video rater at baseline, leaving 97 patients (85.8% of the mITT population) with central video AIMS scores &#x02265;6 at both screening and baseline. Because this population is consistent with the intended study population, the key efficacy endpoints were assessed for this group to inform future study design. As with the mITT population, a significant improvement in AIMS score at week 12 was also observed with deutetrabenazine compared with placebo for this population. Deutetrabenazine provided greater clinical benefit, as evidenced by numeric improvement on CGIC, in patients with a central video AIMS score &#x02265;6 at screening and baseline, suggesting that patients with more severe TD may exhibit better clinical response.</p><p>The chronic, disabling nature of TD<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup> highlights the need for an effective treatment. The significant improvement observed in AIMS score was not fully reflected on CGIC and PGIC outcomes. This may be due to variable symptom appreciation by the clinician and the patient. Most patients in this trial were recruited and evaluated by psychiatrist investigators who may be less familiar with the motor nuances of TD compared with the management of behavioral disorders. Psychiatrists have not been consistently exposed to rigorous training on the scales used in the study. In addition, the dynamic nature of TD itself may limit the ability of these scales to fully capture meaningful change in involuntary movements. It is possible that tolerability issues could have dampened the CGIC and PGIC treatment effects. We believe this is unlikely because the active drug was very well tolerated.</p><p>There was, surprisingly, a notable placebo response among patients on the AIMS rating, which could have also affected the CGIC and PGIC ratings, despite the centralized video assessment. This may be attributed to the patients' perception or expectation of improvement due to the titration design and frequent clinic visits, compounded by the variability over time of TD, which is not often consistently manifested and is very susceptible to external factors such as stress, time of day, and intake of psychotropic medications. In addition, the positive findings of a related study in HD (First Time Use of SD-809 in Huntington Disease [First-HD]) were publically announced while this study was being conducted.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> The placebo effect on AIMS scores was less likely from the central raters because they were blinded to clinical information, concordance with another central rater was required, and all videos of each patient were viewed in the same sitting. Using central video raters reduces the potential for interrater variability<sup><xref rid="R23" ref-type="bibr">23</xref></sup> or visit-specific factors, leading to more standardized measures.</p><p>There are few available treatment options for involuntary movements related to TD. The American Academy of Neurology guidelines do not conclusively recommend off-label use of tetrabenazine for the treatment of TD symptoms (Class III, Level C, Level U).<sup><xref rid="R8" ref-type="bibr">8</xref></sup> This study provides Class I evidence that deutetrabenazine may serve as an efficacious and well-tolerated treatment for abnormal movements in TD, particularly in patients in whom disruption of treatment for underlying psychiatric conditions may not be an option.</p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>The authors thank the patients and site personnel involved with this study and Arianna Grove, PhD (Chameleon Communications International with funding from Teva Pharmaceutical Industries), for editorial assistance in the preparation of this report.</p></ack><sec sec-type="contributions"><title>AUTHOR CONTRIBUTIONS</title><p content-type="contributions">Hubert H. Fernandez, Stewart A. Factor, Robert A. Hauser, Joohi Jimenez-Shahed, William G. Ondo, L. Fredrik Jarskog, Herbert Y. Meltzer, Scott W. Woods, Danny Bega, Mark S. LeDoux, David R. Shprecher, David Stamler, and Karen E. Anderson: significant content-related direction, data acquisition and analysis, contribution to the writing of the draft, and feedback on all relevant materials throughout the development of the manuscript. Charles Davis: significant content-related direction, contribution to the writing of the draft, and feedback on all relevant materials throughout the development of the manuscript. Mat D. Davis: significant content-related direction, statistical analysis, contribution to the writing of the draft, and feedback on all relevant materials throughout the development of the manuscript.</p></sec><sec sec-type="funding"><title>STUDY FUNDING</title><p content-type="funding">This study was funded by Teva Pharmaceutical Industries, Petach Tikva, Israel.</p></sec><sec sec-type="disclosure"><title>DISCLOSURE</title><p content-type="disclosure">H. Fernandez: honoraria: Prime Education Inc, Ohio State University, International Parkinson and Movement Disorders Society, Carling Communications, Medscape (as a speaker in Continuing Medical Education events), Biogen GE Healthcare, Lundbeck, Merz, Pfizer (as a consultant); research support: AbbVie, Acadia, Auspex/Teva, Biotie Therapeutics, Civitas, Kyowa/Prostrakan, Michael J. Fox Foundation, Movement Disorders Society, NIH/National Institute of Neurological Disorders and Stroke, Parkinson Study Group, Rhythm, Synosia; royalties: Demos Publishing; contractual services: AbbVie, Merz Pharmaceuticals, Auspex/Teva, Xeomin Registry Study, Ipsen Pharmaceuticals; stipend: International Parkinson and Movement Disorders Society (for service as medical editor of the Movement Disorders Society website). S. Factor: honoraria: Neurocrine, Lundbeck, Auspex/Teva, Avanir, UCB, Sunovion, US WorldMeds; research support: Ipsen, Allergan, Medtronic, Auspex, US WorldMeds, Pharm-Olam, Cynapsus Therapeutics/Sunovion, Vaccinex, Solstice CHDI Foundation, Michael J. Fox Foundation, NIH; royalties: Demos, Blackwell Futura for textbooks, UpToDate. R. Hauser: consulting: Auspex/Teva, AbbVie, Acadia Pharmaceuticals, Acorda Therapeutics, Adamas Pharmaceuticals, Allergan Neuroscience, AstraZeneca, Biotie Therapies, Chelsea Therapeutics, Cynapsus Therapeutics, Impax Pharmaceuticals, Lundbeck, Michael J. Fox Foundation, Neurocrine Biosciences, Neuropore Therapies, Pfizer, Prexton, UCB Biosciences, and US WorldMeds. J. Jimenez-Shahed: research support: Acadia Pharmaceuticals, St. Jude Medical, Biotie Therapies, Solstice Neurosciences, Avid Radiopharmaceuticals, Michael J. Fox Foundation; consulting: Auspex/Teva, St. Jude Medical, Medtronic. W. Ondo: research support: Lundbeck, Tremor Research Group, Dystonia Coalition, Restless Legs Syndrome Foundation, Acorda; speaker's bureau: Teva, Impax, Lundbeck, UCB, US WorldMeds; consulting: Teva, Lundbeck, Acadia. L. Jarskog: research support: Auspex/Teva, Boehringer Ingelheim, Otsuka, NIH; consulting: Roche. H. Meltzer reports no disclosures relevant to the manuscript. S. Woods: research support: Teva, Pfizer; consulting: Boehringer Ingelheim, Nutria Health. D. Bega: research support: National Parkinson Foundation; speaker's bureau: Acadia Pharmaceuticals, Inc; consulting: Teva, Cynapsus, Acadia. M. LeDoux: speakers' bureau: Lundbeck, Acadia; consulting: Teva Neuroscience, US WorldMeds, Mayo Clinic, Starnes-Davis-Florie, Michael J. Fox Foundation, Benign Essential Blepharospasm Research Foundation, Dorothy/Daniel Gerwin Parkinson's Research Fund, Auspex, Teva, Acorda, CHDI; royalties: Elsevier (for editing <italic>Animal Models of Movement Disorders</italic> and <italic>Movement Disorders: Genetics and Models</italic>). D. Shprecher: consulting: Teva and Lundbeck; speaker's bureau: Teva and Lundbeck; research support: Arizona Alzheimer's Consortium, Adamas, Teva, Kyowa, Michael J. Fox Foundation, Neurocrine, NIH. C. Davis: consultant to Auspex Pharmaceuticals and Teva Pharmaceutical Industries. M. Davis: employee of Teva Pharmaceutical Industries. D. Stamler: employee of Teva Pharmaceutical Industries; personal fees from Auspex Pharmaceuticals outside the submitted work. K. Anderson: Scientific Advisor: North American study co-Principal Investigator for LEGATO-HD (Laquinimod Efficacy and Safety in a Global Trial of Huntington Disease), Global Principal Investigator for AIM-TD (Addressing Involuntary Movements in Tardive Dyskinesia), and Global co-Principal Investigator for ARM-TD. Site Principal Investigator for Pride-HD (Pridopidine Dose Evaluation in Huntington Disease), First-HD, ARC-HD (Alternatives for Reducing Chorea in Huntington Disease): Teva. Scientific Advisor, Site Principal Investigator for ENROLL-HD (A Prospective Registry Study in a Global Huntington Disease Cohort): CHDI Foundation. Scientific Advisor: Prana. Site Principal Investigator: Vaccinex. Consultant to the NeuroNext 105 study with Azevan. Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000003960">Neurology.org</ext-link> for full disclosures.</p></sec><glossary><title>GLOSSARY</title><def-list><def-item><term id="G1">AE</term><def><p>adverse event</p></def></def-item><def-item><term id="G2">AIMS</term><def><p>Abnormal Involuntary Movement Scale</p></def></def-item><def-item><term id="G3">ARM-TD</term><def><p>Aim to Reduce Movements in Tardive Dyskinesia</p></def></def-item><def-item><term id="G4">CGIC</term><def><p>Clinical Global Impression of Change</p></def></def-item><def-item><term id="G5">CI</term><def><p>confidence interval</p></def></def-item><def-item><term id="G6">DRA</term><def><p>dopamine receptor antagonist</p></def></def-item><def-item><term id="G7">First-HD</term><def><p>First Time Use of SD-809 in Huntington Disease</p></def></def-item><def-item><term id="G8">HADS</term><def><p>Hospital Anxiety and Depression Scale</p></def></def-item><def-item><term id="G9">HD</term><def><p>Huntington disease</p></def></def-item><def-item><term id="G10">LS</term><def><p>least-squares</p></def></def-item><def-item><term id="G11">mCDQ-24</term><def><p>modified Craniocervical Dystonia Questionnaire</p></def></def-item><def-item><term id="G12">mITT</term><def><p>modified intent-to-treat</p></def></def-item><def-item><term id="G13">PGIC</term><def><p>Patient Global Impression of Change</p></def></def-item><def-item><term id="G14">QTcF</term><def><p>QT interval corrected with the Fridericia formula</p></def></def-item><def-item><term id="G15">SE</term><def><p>standard error</p></def></def-item><def-item><term id="G16">TD</term><def><p>tardive dyskinesia</p></def></def-item><def-item><term id="G17">VMAT2</term><def><p>vesicular monoamine transporter 2</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aquino</surname><given-names>CCH</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>AE</given-names></name></person-group>
<article-title>Tardive dyskinesia syndromes: current concepts</article-title>. <source>Parkinsonism Relat Disord</source>
<year>2014</year>;<volume>20</volume>(<issue>suppl 1</issue>):<fpage>S113</fpage>&#x02013;<lpage>S117</lpage>.<pub-id pub-id-type="pmid">24262160</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Tarsy</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lungu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Baldessarini</surname><given-names>RJ</given-names></name></person-group>
<article-title>Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>William</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Eduardo</surname><given-names>T</given-names></name></person-group>, editors. <source>Handbook of Clinical Neurology</source>. <publisher-loc>Amsterdam, Netherlands</publisher-loc>: <publisher-name>Elsevier</publisher-name>; <year>2011</year>:<fpage>601</fpage>&#x02013;<lpage>616</lpage>.</mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woods</surname><given-names>SW</given-names></name>, <name name-style="western"><surname>Morgenstern</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Saksa</surname><given-names>JR</given-names></name>, <etal>et al</etal></person-group>
<article-title>Incidence of tardive dyskinesia with atypical and conventional antipsychotic medications: prospective cohort study</article-title>. <source>J Clin Psychiatry</source>
<year>2010</year>;<volume>71</volume>:<fpage>463</fpage>&#x02013;<lpage>474</lpage>.<pub-id pub-id-type="pmid">20156410</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samie</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Dannenhoffer</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Rozek</surname><given-names>S</given-names></name></person-group>
<article-title>Life-threatening tardive dyskinesia caused by metoclopramide</article-title>. <source>Mov Disord</source>
<year>1987</year>;<volume>2</volume>:<fpage>125</fpage>&#x02013;<lpage>129</lpage>.<pub-id pub-id-type="pmid">3504264</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waln</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Jankovic</surname><given-names>J</given-names></name></person-group>
<article-title>An update on tardive dyskinesia: from phenomenology to treatment</article-title>. <source>Tremor Other Hyperkinetic Mov</source>
<year>2013</year>;<volume>3</volume>:<fpage>tre-03-161-4138-4131</fpage>.</mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jankelowitz</surname><given-names>SK</given-names></name></person-group>
<article-title>Treatment of neurolept-induced tardive dyskinesia</article-title>. <source>Neuropsychiatr Dis Treat</source>
<year>2013</year>;<volume>9</volume>:<fpage>1371</fpage>&#x02013;<lpage>1380</lpage>.<pub-id pub-id-type="pmid">24072972</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhidayasiri</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Boonyawairoj</surname><given-names>S</given-names></name></person-group>
<article-title>Spectrum of tardive syndromes: clinical recognition and management</article-title>. <source>Postgrad Med J</source>
<year>2011</year>;<volume>87</volume>:<fpage>132</fpage>&#x02013;<lpage>141</lpage>.<pub-id pub-id-type="pmid">21131613</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhidayasiri</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fahn</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Weiner</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Gronseth</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Sullivan</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Zesiewicz</surname><given-names>TA</given-names></name></person-group>
<article-title>Evidence-based guideline: treatment of tardive syndromes</article-title>. <source>Neurology</source>
<year>2013</year>;<volume>81</volume>:<fpage>463</fpage>&#x02013;<lpage>469</lpage>.<pub-id pub-id-type="pmid">23897874</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caroff</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Hurford</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Lybrand</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Campbell</surname><given-names>EC</given-names></name></person-group>
<article-title>Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial</article-title>. <source>Neurol Clin</source>
<year>2011</year>;<volume>29</volume>:<fpage>127</fpage>&#x02013;<lpage>148</lpage>.<pub-id pub-id-type="pmid">21172575</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cloud</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Zutshi</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Factor</surname><given-names>SA</given-names></name></person-group>
<article-title>Tardive dyskinesia: therapeutic options for an increasingly common disorder</article-title>. <source>Neurotherapeutics</source>
<year>2014</year>;<volume>11</volume>:<fpage>166</fpage>&#x02013;<lpage>176</lpage>.<pub-id pub-id-type="pmid">24310603</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zutshi</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Cloud</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Factor</surname><given-names>SA</given-names></name></person-group>
<article-title>Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a University-based movement disorder clinic</article-title>. <source>Tremor Other Hyperkinetic Mov</source>
<year>2014</year>;<volume>4</volume>:<fpage>266</fpage>.</mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rana</surname><given-names>AQ</given-names></name>, <name name-style="western"><surname>Chaudry</surname><given-names>ZM</given-names></name>, <name name-style="western"><surname>Blanchet</surname><given-names>PJ</given-names></name></person-group>
<article-title>New and emerging treatments for symptomatic tardive dyskinesia</article-title>. <source>Drug Des Devel Ther</source>
<year>2013</year>;<volume>7</volume>:<fpage>1329</fpage>&#x02013;<lpage>1340</lpage>.</mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><collab>Huntington Study Group</collab>. <article-title>Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial</article-title>. <source>Neurology</source>
<year>2006</year>;<volume>66</volume>:<fpage>366</fpage>&#x02013;<lpage>372</lpage>.<pub-id pub-id-type="pmid">16476934</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="book">XENAZINE Prescribing Information. <publisher-loc>Deerfield, IL</publisher-loc>: <publisher-name>Lundbeck</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guay</surname><given-names>DR</given-names></name></person-group>
<article-title>Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders</article-title>. <source>Am J Geriatr Pharmacother</source>
<year>2010</year>;<volume>8</volume>:<fpage>331</fpage>&#x02013;<lpage>373</lpage>.<pub-id pub-id-type="pmid">20869622</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hewitt</surname><given-names>MC</given-names></name></person-group>
<article-title>The kinetic isotope effect in the search for deuterated drugs</article-title>. <source>Drug News Perspect</source>
<year>2010</year>;<volume>23</volume>:<fpage>398</fpage>&#x02013;<lpage>404</lpage>.<pub-id pub-id-type="pmid">20697607</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stamler</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bradbury</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>F</given-names></name></person-group>
<article-title>The pharmacokinetics and safety of deuterated-tetrabenazine</article-title>. <source>Neurology</source>
<year>2013</year>;<volume>80</volume>:<fpage>P07.210</fpage>.</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Timmins</surname><given-names>GS</given-names></name></person-group>
<article-title>Deuterated drugs: where are we now?</article-title>
<source>Expert Opin Ther Patents</source>
<year>2014</year>;<volume>24</volume>:<fpage>1067</fpage>&#x02013;<lpage>1075</lpage>.</mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><collab>Huntington Study Group</collab>, <person-group person-group-type="author"><name name-style="western"><surname>Frank</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Testa</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Stamler</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial</article-title>. <source>JAMA</source>
<year>2016</year>;<volume>316</volume>:<fpage>40</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">27380342</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epping</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>JI</given-names></name>, <name name-style="western"><surname>Craufurd</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Longitudinal psychiatric symptoms in prodromal Huntington's disease: a decade of data</article-title>. <source>Am J Psychiatry</source>
<year>2016</year>;<volume>173</volume>:<fpage>184</fpage>&#x02013;<lpage>192</lpage>.<pub-id pub-id-type="pmid">26472629</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casey</surname><given-names>DE</given-names></name></person-group>
<article-title>Tardive dyskinesia</article-title>. <source>West J Med</source>
<year>1990</year>;<volume>153</volume>:<fpage>535</fpage>&#x02013;<lpage>541</lpage>.<pub-id pub-id-type="pmid">1979705</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rittmannsberger</surname><given-names>H</given-names></name></person-group>
<article-title>Ten year outcome of tardive dyskinesia during continuous treatment with first generation antipsychotics</article-title>. <source>Psychiatr Danub</source>
<year>2008</year>;<volume>20</volume>:<fpage>461</fpage>&#x02013;<lpage>465</lpage>.<pub-id pub-id-type="pmid">19011586</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haidet</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Tate</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Divirgilio-Thomas</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kolanowski</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Happ</surname><given-names>MB</given-names></name></person-group>
<article-title>Methods to improve reliability of video-recorded behavioral data</article-title>. <source>Res Nurs Health</source>
<year>2009</year>;<volume>32</volume>:<fpage>465</fpage>&#x02013;<lpage>474</lpage>.<pub-id pub-id-type="pmid">19434651</pub-id></mixed-citation></ref></ref-list></back></article>